Mylan Laboratories Ltd (MATRIXLABS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524794 | NSE: MATRIXLABS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

Mylan Laboratories Ltd (MATRIXLABS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524794 | NSE: MATRIXLABS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Mylan Laboratories

Based on:

M-Cap below 100cr DeciZen not available

Mylan Laboratories stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
18.02
Market Cap:
3,273 Cr.
52-wk low:
208.8
52-wk high:
211

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Mylan Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 5.7%2.8%1.3%3.1%3%8.2%11.2%7%4.9%7.9%-
Value Creation
Index
-0.6-0.8-0.9-0.8-0.8-0.4NANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7,8579,4679,6239,63810,96912,23912,95811,54310,7149,71212,239
Sales YoY Gr.-20.5%1.6%0.2%13.8%11.6%5.9%-10.9%-7.2%-9.4%-
Adj EPS -8.7-13.3-27.4-24.6-22.32.834.917.213.917.211.6
YoY Gr.-NANANANANA1147.1%-50.8%-19%23.8%-
BVPS (₹) 239.8280.3333.2316294.7289.9352.7375.2390.5230.156.7
Adj Net
Profit
-165-323-667-598-54268.1850418339420182
Cash Flow from Ops. 6792561,6052,1011,3251,6863,2903,0302,0612,107-
Debt/CF from Ops. 10.342.85.84.16.54.921.721.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 2.4%-2.4%-9.2%-9.4%
Adj EPS NANA-21%23.8%
BVPS-0.5%-4.8%-13.3%-41.1%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-3.7-5.6-8.9-7.6-7.3110.94.73.65.68.1
Op. Profit
Mgn %
12.713.315.3191618.619.714.814.515.220.1
Net Profit
Mgn %
-2.1-3.4-6.9-6.2-4.90.66.63.63.24.31.5
Debt to
Equity
1.51.61.11.11.21.20.80.60.40.7-
Working Cap
Days
3553603643593443293213493643590
Cash Conv.
Cycle
1521621992011871921972142232170

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Mylan Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 11.6 -30
TTM Sales (₹ Cr.) 12,239 9,623
BVPS (₹.) 56.7 517.8
Reserves (₹ Cr.) 855 8,064
P/BV 3.69 0.40
PE 18.02 0.00
From the Market
52 Week Low / High (₹) 208.80 / 211.00
All Time Low / High (₹) 0.42 / 312.80
Market Cap (₹ Cr.) 3,273
Equity (₹ Cr.) 31.3
Face Value (₹) 2
Industry PE 39.4

Management X-Ray of Mylan Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Mylan Laboratories - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Mylan Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales7,857.169,467.289,622.849,637.9910,969.0412,238.5712,958.2611,543.2210,713.529,711.72
Operating Expenses 6,864.618,216.438,198.297,806.279,231.399,972.3610,458.749,921.789,177.778,280.92
Manufacturing Costs1,501.681,547.131,542.601,327.531,731.091,690.701,708.631,887.662,121.59868.02
Material Costs3,984.354,741.474,746.714,477.785,549.356,107.306,230.205,591.584,535.844,892.37
Employee Cost 645.21809.971,007.961,064.381,106.041,195.461,433.261,471.441,577.881,414.45
Other Costs 733.381,117.86901.02936.58844.92978.901,086.65971.09942.461,106.08
Operating Profit 992.551,250.851,424.551,831.731,737.652,266.212,499.521,621.441,535.761,430.80
Operating Profit Margin (%) 12.6%13.2%14.8%19.0%15.8%18.5%19.3%14.0%14.3%14.7%
Other Income 495.34349.98476.26500.20308.79246.78479.93457.74241.5249.98
Interest 568.63716.46856.94816.97827.76849.91744.26550.82239.03413.36
Depreciation 851.901,190.801,681.191,805.901,567.231,244.571,262.871,053.961,092.76576
Exceptional Items 0000000000
Profit Before Tax 67.36-306.42-637.32-290.94-348.54418.50972.32474.39445.49491.42
Tax -66.93-171.67-167.7739.9459.73236.88-140-168.45-34.8285.17
Profit After Tax 134.28-134.75-469.55-330.89-408.27181.621,112.31642.83480.31406.25
PAT Margin (%) 1.7%-1.4%-4.9%-3.4%-3.7%1.5%8.6%5.6%4.5%4.2%
Adjusted EPS (₹)7.1-5.5-19.3-13.6-16.87.545.726.419.716.7
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 4,538.876,825.338,112.637,694.537,175.087,059.688,588.209,137.179,509.345,602.84
Share Capital 37.8648.7048.7048.7048.7048.7048.7048.7048.7048.70
Reserves 4,501.016,776.638,063.937,645.837,126.377,010.988,539.509,088.479,460.635,554.14
Minority Interest0000000000
Debt6,888.5210,638.568,939.718,268.438,471.558,240.806,6645,126.264,077.893,729.28
Long Term Debt6,778.2710,1988,738.668,268.438,471.558,240.805,940.214,178.903,1533,729.28
Short Term Debt110.24440.56201.05000723.79947.36924.890
Trade Payables1,637.181,815.391,578.112,043.912,371.702,069.762,318.332,025.962,703.712,156.32
Others Liabilities 2,839.042,809.211,523.561,388.451,143.582,034.511,481.871,230.311,250.331,080.48
Total Liabilities 15,903.6022,088.5020,154.0119,395.3319,161.9119,404.7619,052.3917,519.7017,541.2612,568.91

Fixed Assets

Gross Block7,722.2413,726.8614,727.0515,371.2415,780.6916,582.0817,327.6117,532.3018,421.5810,785.02
Accumulated Depreciation1,712.272,917.824,589.276,295.397,832.898,744.9810,050.1311,188.6612,235.397,322.94
Net Fixed Assets 6,009.9710,809.0410,137.789,075.867,947.807,837.107,277.486,343.646,186.193,462.09
CWIP 941.23804.67762.06366.53328.27434.62369.07609.12525.94712.41
Investments 163.020.230.230.230.230.230.230.230.230
Inventories3,157.123,759.333,477.253,815.904,735.744,439.144,537.974,910.115,421.953,309.77
Trade Receivables2,139.693,126.333,603.753,607.043,669.755,083.775,012.983,914.853,945.163,631
Cash Equivalents 113.92383.74173.7788.7084.10179.5867.0538.905.18126.23
Others Assets 3,378.663,205.151,999.182,441.092,396.031,430.321,787.621,702.861,456.631,327.42
Total Assets 15,903.6022,088.5020,154.0119,395.3319,161.9119,404.7619,052.3917,519.7017,541.2612,568.91

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 679.16256.181,605.092,101.051,324.661,685.963,290.303,029.982,061.332,107
PBT 67.36-306.42-637.32-290.94-348.54418.50972.32474.39445.49491.42
Adjustment 1,514.711,925.292,777.572,202.642,585.052,573.111,922.271,678.341,495.221,309.74
Changes in Working Capital -837.12-1338.35-511.81213.64-902-1300.38423.98905125.27327.31
Tax Paid -65.78-24.33-23.35-24.29-9.85-5.27-28.26-27.74-4.64-21.46
Cash Flow From Investing Activity -469.03-5,793.96-568.66-632.12-372.15-421.19-764.05-840.95-659.94-1,015.12
Capex -585.97-716.32-931.92-511.28-358.36-497.50-906.39-857.38-906.47-1,020.33
Net Investments 125.66-47.64272.370000000
Others -8.71-5,03090.89-120.84-13.7976.31142.3416.43246.535.21
Cash Flow From Financing Activity -279.925,574.30-966.63-1,553.71-960.36-1,118.32-2,638.74-2,217.03-1,433.78-815.70
Net Proceeds from Shares 02,476.8800000000
Net Proceeds from Borrowing 00204.3800000-921.810
Interest Paid -568.50-702.07-935.10-918.28-935.02-955.98-878.97-702.12-469.60-604.61
Dividend Paid 0000000000
Others 288.583,799.50-235.92-635.43-25.34-162.35-1,759.77-1,514.91-42.37-211.09
Net Cash Flow -69.7936.5269.79-84.77-7.85146.45-112.48-27.99-32.39276.18

Finance Ratio

PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)3.08-2.37-6.29-4.19-5.492.5514.227.255.155.38
ROCE (%)5.662.781.253.132.998.1711.246.954.927.9
Asset Turnover Ratio0.520.50.460.490.570.630.670.630.610.65
PAT to CFO Conversion(x)5.06N/AN/AN/AN/A9.282.964.714.295.19
Working Capital Days
Receivable Days102101128137121131142141134142
Inventory Days130133137138142137126149176164
Payable Days149133130148145133129142190181

Mylan Laboratories Ltd Stock News

Mylan Laboratories Ltd FAQs

The current trading price of Mylan Laboratories on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Mylan Laboratories stood at ₹3,273.
The latest P/E ratio of Mylan Laboratories as of 31-Dec-1969 is 18.02.
The latest P/B ratio of Mylan Laboratories as of 31-Dec-1969 is 3.69.
The 52-week high of Mylan Laboratories is ₹211.0 and the 52-week low is ₹208.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mylan Laboratories is ₹12,239 ( Cr.) .

About Mylan Laboratories Ltd

Matrix Laboratories (MLL), incorporated in the year 1985, is a subsidiary of US based company Mylan Inc. It is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms.

MLL has manufacturing facilities located in four locations in Hyderabad and Visakhapatnam, here it manufactures wide range of APIs. The company also has solid oral dosage forms facility located in Nashik. All its manufacturing plants are approved by US FDA, EDQM -EU, TGA (Australia) and has also received ISO-9000, ISO 14000 certifications. One of the core business activities of MLL is research and development of new APIs. It also offers contract research and development services for earlier stages of development and contract manufacturing for projects that have advanced further into development and are being considered for commercial manufacturing.

Mylan Inc had acquired 71.5% stake in Matrix Laboratories in 2007 for USD 736 million. Since then, the US firm has successfully integrated the two organisations, along with the generics business of Merck KGaA, to build a global, high quality pharmaceutical platform with $5.5 billion revenues in 2010.

Products

Matrix Laboratories is one of the world’s largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) for a wide range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs.

Milestones

August 2009 - Matrix becomes a privately held Mylan subsidiary

June 2009 - Mylan announces successful Matrix delisting offer

January 2007 - Mylan Laboratories acquires a 71.5% controlling interest in Matrix Laboratories Limited

January 2007 - Matrix receives “Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2006

May 2006 - Matrix receives “Best Management” award from the government of Andhra Pradesh

December 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2005

December 2005 - Matrix announces decision to acquire controlling stake in Concord Biotech, an Ahmedabad-based biotechnology company with fermentation and bio-catalytic technology capabilities and U.S. Food and Drug Administration (FDA) approved API manufacturing facilities

November 2005 - Matrix receives the National Award for R&D Efforts in Industry for 2005 in Pharmaceuticals/Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology

June 2005 - Matrix Laboratories Limited acquires a controlling stake in Docpharma, based in Belgium

April 2005 - Matrix and Aspen Pharmacare Holdings Limited form joint ventures in India and South Africa

February 2005 - Matrix announces strategic alliance with MCHEM Pharma Group of China

January 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2004

January 2005 - Matrix purchases finished dosage facility located near Nashik, about 150 km from Mumbai

April 2004 - Matrix signs definitive agreements with India Newbridge Investments Limited and Maxwell (Mauritius) Pte. Limited

March 2004 - Matrix’s Board of Directors approves the company’s merger with Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited

March 2004 - Matrix receives U.S. FDA approval for its manufacturing facility at Jeedimetla, near Hyderabad

November 2003 - Matrix sets up two 50:50 joint venture companies, one in India and the other in Ireland

October 2003 - Matrix signs an agreement with the William J. Clinton Foundation to supply ARVs for the treatment of HIV/AIDS patients in sub-Saharan Africa, South Africa and the Caribbean countries

May 2003 - Matrix merges with Vorin Laboratories Limited and Medicorp Technologies India Limited

April 2003 - Matrix successfully files process patent applications for four products at the Indian Patent Office

Awards

In the year 2006 the company received “Best Management Award” from the Government of Andhra Pradesh

It received National Award for R&D Efforts in Industry in Pharmaceuticals /Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology in 2005.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×